Skip to main content
Journal of Assisted Reproduction and Genetics logoLink to Journal of Assisted Reproduction and Genetics
. 1999 Sep;16(8):425–430. doi: 10.1023/A:1020569508927

Requirements for Human Chorionic Gonadotropin and Recombinant Human Luteinizing Hormone for Follicular Development and Maturation

Claus Yding Andersen 1, Søren Ziebe 1, Xia Guoliang 1, Anne Grete Byskov 1
PMCID: PMC3455491  PMID: 10478322

Abstract

Purpose:Our purpose was to evaluate the requirements for human chorionic gonadotropin (hCG) and recombinant luteinizing hormone (rec-LH) for follicular development and maturation in mice.

Methods:We carried out ovarian stimulation of immature mice. Output parameters were the preembryos created in vivo and frequency of blastocyst formation in vitro.

Results:hCG at 0 to 1 IU resulted in a dose-dependent recovery of preembryos (0 to 39.7 ± 4.3; mean ± SE) per mouse. hCG at 1 and 10 hCG gave similar results, whereas higher doses significantly reduced the number of preembryos. Potential for blastocyst formation was independent of hCG dose. hCG and rec-LH together exerted a synergistic effect on the recovery of preembryos.

Conclusions:Optimal follicular development required a combination of 20 IU follicle stimulating hormone and 1–10 IU hCG. The potency of hCG was higher than that of rec-LH, but a synergistic effect of rec-LH and hCG was observed. The results may be pertinent for the development of strategies for ovarian stimulation of women with low levels of endogenous LH.

Keywords: ovarian stimulation, oocyte maturation, human chorionic gonadotropin, recombinant luteinizing hormone, follicle stimulating hormone, preembryos, blastocysts

Full Text

The Full Text of this article is available as a PDF (873.5 KB).

REFERENCES

  • 1.Chappel S, Howles C. Reevaluation of the roles of lutenizing hormone and follicle-stimulating hormone in the ovulatory process. Hum Reprod. 1991;6:1206–1212. doi: 10.1093/oxfordjournals.humrep.a137513. [DOI] [PubMed] [Google Scholar]
  • 2.Shoham Z, Jacobs HS, Insler V. Lutenizing hormone: its role, mechanism of action, and detrimental effects when hypersecreted during the follicular phase. Fertil Steril. 1993;59:1153–1161. doi: 10.1016/s0015-0282(16)55968-8. [DOI] [PubMed] [Google Scholar]
  • 3.Howles C, MacName MC, Edwards RG. Effect of high tonic levels of luteinizing hormone on outcome of in vitro fertilization. Lancet. 1986;2:521–522. doi: 10.1016/s0140-6736(86)90395-8. [DOI] [PubMed] [Google Scholar]
  • 4.Conway GS, Honour JW, Jacobs HS. Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features. Clin Endorcrinol. 1989;30:459–470. doi: 10.1111/j.1365-2265.1989.tb00446.x. [DOI] [PubMed] [Google Scholar]
  • 5.Regan L, Owen EJ, Jacobs HS. Hypersecretion of luteinizing hormone, infertility and miscarriage. Lancet. 1989;336:1141–1144. doi: 10.1016/0140-6736(90)92765-a. [DOI] [PubMed] [Google Scholar]
  • 6.Westergaard LG, Erb K, Laursen S, Rex S, Rasmussen PE. The effect of human menopausal gonadotropin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotropic women. Hum Reprod. 1996;11:1209–1213. doi: 10.1093/oxfordjournals.humrep.a019357. [DOI] [PubMed] [Google Scholar]
  • 7.Agrawal R, Conway GS, Engmann L. Implications of using follicle-stimulating hormone preparations depleted of luteinizing hormone to achieve follicular growth in in vitro fertilization. Gynecol Endocrinol. 1998;12:9–15. doi: 10.3109/09513599809024964. [DOI] [PubMed] [Google Scholar]
  • 8.Balasch J, Miro F, Burzaco I. The role of luteinizing hormone in human follicle development and oocyte fertility: Evidence from in-vitro fertilization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human follicle stimulating hormone. Hum Reprod. 1995;10:1678–1683. doi: 10.1093/oxfordjournals.humrep.a136154. [DOI] [PubMed] [Google Scholar]
  • 9.Shoham Z, Balen A, Patel A. Results of ovulation induction using human menopausal gonadotropin or purified follicle-stimulating hormone in hypogonadotropin hypogonadism patients. Fertil Steril. 1991;56:1048–1053. doi: 10.1016/s0015-0282(16)54715-3. [DOI] [PubMed] [Google Scholar]
  • 10.Shoham Z. Effects of different menotropin preparations for ovulation induction in hypogonadotropic women. In: Fillicori M, editor. The Role of Luteinizing Hormone in Folliculogenesis and Ovulation Induction. Bologna: Monduzzi Editore; 1999. pp. 105–114. [Google Scholar]
  • 11.Gordon UD. Effects of different menotropin preparations for assisted reproduction in hypogonadotropic hypogonadism. In: Fillicori M, editor. The Role of Luteinizing Hormone in Folliculogenesis and Ovulation Induction. Bologna: Monduzzi Editore; 1999. pp. 135–144. [Google Scholar]
  • 12.Westergaard LG. Clinical outcome of in-vitro fertilization: hMG versus purified FSH. In: Fillicori M, editor. The Role of Luteinizing Hormone in Folliculogenesis and Ovulation Induction. Bologna: Monduzzi Editore; 1999. pp. 173–188. [Google Scholar]
  • 13.Ziebe S, Guoliang X, Byskov AG. Impact of gonadotropin dose on pre-embryo recovery and development in superovulated mice. Hum Reprod. 1993;8:385–388. doi: 10.1093/oxfordjournals.humrep.a138056. [DOI] [PubMed] [Google Scholar]
  • 14.Mannaerts B, Leeuw R, Geelen J. Comparative in vitro and in vivo studies on the biological characteristics of recombinant human follicle-stimulating hormone. Endocrinology. 1991;129:2623–2630. doi: 10.1210/endo-129-5-2623. [DOI] [PubMed] [Google Scholar]
  • 15.Yding Andersen C, Westergaard LG, Byskov AG, Erb K. Reduced in vitro fertilization of human oocytes correlates with raised circulating FSH levels during ovarian stimulation in normogonadotrophic women downregulated with GnRH-analogues. J Assist Reprod Genet. 1997;14:581–588. doi: 10.1023/A:1022528617732. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Couzinet B, Lestrat N, Brailly S. Stimulation of ovarian follicular maturation with pure follicle-stimulating hormone in women with gonadotropin deficiency. J Clin Endocrinol Metab. 1988;66:552–556. doi: 10.1210/jcem-66-3-552. [DOI] [PubMed] [Google Scholar]
  • 17.Flemming R, Lloyd F, Herbert M. Effects of profound suppression on luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone. Hum Reprod. 1998;13:1788–1792. doi: 10.1093/humrep/13.7.1788. [DOI] [PubMed] [Google Scholar]
  • 18.Wang XN, Greenwald GS. Human chorionic gonadotropin or human recombinant follicle-stimulating hormone(FSH)-induced ovulation and subsequent fertilization and early embryo development in hypophysectiomized FSH-primed mice. Endocrinology. 1993;132:2009–2016. doi: 10.1210/endo.132.5.8477652. [DOI] [PubMed] [Google Scholar]
  • 19.Wang XN, Greenwald GS. Hypophysectomy of the cyclic mouse. II. Effects of follicle-stimulating hormone (FSH) and luteinizing hormone on folliculogenesis, FSH and human chrorionc gonadotropin receptors, and steroidogenesis. Biol Reprod. 1993;48:595–605. doi: 10.1095/biolreprod48.3.595. [DOI] [PubMed] [Google Scholar]
  • 20.Stokman PG, de Leeuw R, van den Wijngaard HA. Human chorionic gonadotropins in commercial menopausal gonadotropin preparations. Fertil Steril. 1993;60:175–178. doi: 10.1016/s0015-0282(16)56059-2. [DOI] [PubMed] [Google Scholar]
  • 21.Odell WD, Griffin J. Pulsatile secretion of chorionic gonadotropin during the normal menstrual cycle. J Clin Endocrinol Metab. 1989;69:528–532. doi: 10.1210/jcem-69-3-528. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Assisted Reproduction and Genetics are provided here courtesy of Springer Science+Business Media, LLC

RESOURCES